Long Term Care Journal
Wednesday, May 30, 2018
FDA approves new treatment for moderately to severely active ulcerative colitis - FDA Press Releases
FDA today expanded the approval of Xeljanz (tofacitinib) to include adults with moderately to severely active ulcerative colitis.
from Food and Drug Administration--Press Releases https://ift.tt/2J1qP27
via
IFTTT
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment